This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data."

Transcription

1 abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical study report had been prepared in accordance with best practice and applicable legal and regulatory requirements at the time of study completion. The synopsis may include approved and non approved uses, doses, formulations, treatment regimens and/or age groups; it has not necessarily been submitted to regulatory authorities. A synopsis is not intended to provide a comprehensive analysis of all data currently available regarding a particular drug. More current information regarding a drug is available in the approved labeling information which may vary from country to country.. Additional information on this study and the drug concerned may be provided upon request based on s Policy on Transparency and Publication of Clinical Study Data. The synopsis is supplied for informational purposes only in the interests of scientific disclosure. It must not be used for any commercial purposes and must not be distributed, published, modified, reused, posted in any way, or used for any other purpose without the express written permission of.

2

3 Page 2 of 10 BI Trial No.: c International GmbH or one or more of its affiliated companies 2 of International GmbH or one or more of its affiliated companies. All rights reserved. Table 1: Patients entered, treated, and analysed (primary endpoint) Entered Treated Analysed Placebo Tiotropium 5 µg Tio+Olo 2.5/5 µg Tio+Olo 5/5 µg Diagnosis: Main Criteria for Inclusion: BI Investigational Product: Dose: Mode of Admin.: Batch No.: BI Investigational Product: Dose: Mode of Admin.: Batch No.: COPD Outpatients with COPD 40 years old, smoking history of >10 pack years, postbronchodilator FEV 1 30% and <80% of predicted normal, Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage II III, and post-bronchodilator FEV 1 / forced vital capacity (FVC) <70%. Tiotropium+Olodaterol (Tio+Olo) inhalation solution - RESPIMAT 2.5 μg tiotropium / 5 μg olodaterol (1.25 μg µg, respectively, per actuation Oral inhalation B Tio+Olo inhalation solution - RESPIMAT 5 μg tiotropium / 5 μg olodaterol (2.5 µg each per actuation) Oral inhalation B

4 Page 3 of 10 BI Trial No.: c International GmbH or one or more of its affiliated companies 3 of International GmbH or one or more of its affiliated companies. All rights reserved. Comparator Product: Dose: Mode of Admin.: Batch No.: Comparator Product: Dose: Mode of Admin.: Batch No.: Duration of Treatment: Criteria for Evaluation: Efficacy: Safety: Tiotropium inhalation solution - RESPIMAT 5 μg (2.5 µg per actuation) Oral inhalation B Placebo inhalation solution RESPIMAT Oral inhalation B weeks. The duration of the trial for each patient was 18 weeks: 1-week run-in period, 2-week screening period, 12-week treatment period, and 3-week follow-up period Primary efficacy endpoints: FEV 1 area under the curve (AUC) 0-3h response (change from baseline) after 12 weeks of treatment Trough FEV 1 response (change from baseline) after 12 weeks of treatment SGRQ total score after 12 weeks of treatment Secondary efficacy endpoints: Transitional Dyspnoea Index (TDI) focal score after 12 weeks of treatment FVC AUC 0-3h response (change from baseline) after 12 weeks of treatment Trough FVC response (change from baseline) after 12 weeks of treatment Further (non-secondary) endpoints are not presented here. The assessment of safety was based on routine safety monitoring and reporting through adverse events, serious adverse events, physical examination, pulse rate and blood pressure pre-dose and post-dose at Visits 2 and 5, and treatment exposure.

5 Page 4 of 10 BI Trial No.: c International GmbH or one or more of its affiliated companies 4 of International GmbH or one or more of its affiliated companies. All rights reserved. Statistical Methods: SUMMARY - CONCLUSIONS: Trial Subjects and Compliance with Trial Protocol: The primary analysis was performed on the full analysis set (FAS). Comparisons between treatment groups for change from baseline in FEV 1 AUC 0-3h, change from baseline in trough FEV 1, and SGRQ total score were analysed using a restricted maximum likelihood (REML)-based mixed effects model for repeated measures (MMRM) approach. The MMRM model included treatment, test day and treatment by test day interaction as fixed, categorical effects, baseline and baseline-by-test day interaction as continuous fixed covariates, and patient as random effect. A spatial power (co)variance structure was used to model the within-patient errors. The Kenward-Roger approximation was used to estimate denominator degrees of freedom. Adjusted mean values were presented together with p-values and 95% confidence intervals (CI). The empirical sandwich estimator approach was used as sensitivity analysis. For the 3 primary endpoints, Tio+Olo 5/5 µg and Tio+Olo 2.5/5 µg were tested vs. placebo in a pre-defined sequential testing scheme. For the third primary endpoint, SGRQ total score, the data from this trial ( ) were also combined with data from the replicate trial ( ). The primary treatment comparison was the contrast between treatment groups after 12 weeks of treatment. Statistical significance was declared if 2-sided hypothesis tests were rejected at the 0.05 significance level, the treatment effect favoured the Tio+Olo fixed dose combination (FDC) vs. placebo, and all previous hypothesis tests in the pre-defined hierarchy had shown statistical significance. Further comparisons between treatment groups (i.e. Tio+Olo 5/5 µg and Tio+Olo 2.5/5 µg vs. Tio 5 µg, Tio 5 µg vs. placebo, and Tio+Olo 5/5 µg vs. Tio+Olo 2.5/5) were performed as descriptive analyses (i.e. not protected by the overall type I error at the 0.05 level). A total of 809 patients were randomised and treated. Of these, 764 patients (94.4%) completed the trial and 45 patients (5.6%) discontinued study medication prematurely. The only reason for premature discontinuation reported for >1% of patients was occurrence of adverse events (AEs, 2.8% overall). Premature study medication discontinuation was more frequent in the placebo group (9.9%) than in the active treatment groups (tiotropium [Tio] 5 µg: 5.9%, tiotropium + olodaterol

6 Page 5 of 10 BI Trial No.: c International GmbH or one or more of its affiliated companies 5 of International GmbH or one or more of its affiliated companies. All rights reserved. Efficacy Results: [T+O] 5/5 µg: 2.0%, T+O 2.5/5 µg: 4.5%). Twenty-two of the 809 treated patients (2.7%) had at least 1 important protocol violation (IPV) during the trial. The incidence of IPVs was similar in all treatment groups (2.0 to 3.5%). Demographic characteristics were generally well balanced among the 4 treatment groups. The majority of patients were White (96.3%) and male (62.5%). The percentage of male patients was slightly lower in the placebo group (57.9%) than in the active treatment groups (62.4% to 65.8%). The overall mean age was 64.6 years (standard deviation 8.4 years). In line with the inclusion criteria, all patients were aged 40 years (range 41 to 92 years), and all were ex-smokers (54.5%) or current smokers (45.5%). The overall mean smoking history was 49.3 pack-years (range 11 to 208 pack-years). Efficacy results from lung function endpoints presented in this report are based on analyses of the data from trial Efficacy results from SGRQ and Mahler TDI score endpoints presented in this report are based on both the individual dataset from trial and the combined dataset from and Primary efficacy endpoints: The primary lung function endpoints for this trial were the FEV 1 AUC 0-3h response (change from baseline) and trough FEV 1 response assessed after 12 weeks of treatment (based on the individual data from this trial). The primary symptomatic endpoint was the SGRQ total score after 12 weeks of treatment based on the individual data from this trial as well as the combined data from this trial and the replicate trial The Tio+Olo FDCs were superior to placebo for both primary lung function endpoints and for the primary symptomatic endpoint (p<0.05, 2-sided) based on all pre-defined hypothesis tests. Sensitivity analyses yielded similar results to those of the primary analyses. The adjusted mean FEV 1 AUC 0-3h responses after 12 weeks were larger for the Tio+Olo FDCs than for placebo or Tio 5 µg (placebo: [standard error [SE] [ 0.4] L, Tio 5 μg: [0.3] L, T+O 2.5/5 μg: [0.4] L, T+O 5/5 μg: [0.3] L). The improvement over placebo after 12 weeks was L for Tio+Olo 5/5 µg and L for Tio+Olo 2.5/5 µg (p<0.00 for both

7 Page 6 of 10 BI Trial No.: c International GmbH or one or more of its affiliated companies 6 of International GmbH or one or more of its affiliated companies. All rights reserved. comparisons). The adjusted mean trough FEV 1 responses after 12 weeks were also larger for the Tio+Olo FDCs than for placebo or Tio 5 µg (placebo: [SE 0.4] L, Tio 5 μg: [0.3] L, T+O 2.5/5 μg: [0.3] L, T+O 5/5 μg: [0.3] L). The improvement over placebo was L for Tio+Olo 5/5 μg and L for Tio+Olo 2.5/5 μg (p<0.00 for both comparisons). The adjusted mean SGRQ total score after 12 weeks of treatment was lower (better) for the Tio+Olo FDCs than for placebo or Tio 5 µg in both, the individual trial data from (placebo: , [SE 0.711] points, Tio 5 μg: [0.694] points, T+O 2.5/5 μg: [0.691] points, T+O 5/5 μg: 38.1 [0.683] points) and the combined trial data (placebo: [0.511] points, Tio 5 μg: [0.498] points, T+O 2.5/5 μg: [0.494] points, T+O 5/5 μg: [0.492] points). The scores obtained from both data sources (individual and combined data) were comparable. Based on the data from trial , the treatment difference in the adjusted mean SGRQ total score was points for Tio+Olo 5/5 μg vs. placebo and points for Tio+Olo 2.5/5 μg vs. placebo (p<0.00 and p = , respectively). Based on the combined data, the treatment difference in the adjusted mean SGRQ total score was points for Tio+Olo 5/5 μg vs. placebo and points for Tio+Olo 2.5/5 μg vs. placebo (p<0.00 for both comparisons). Consequently, all confirmatory hypotheses were met in this trial. The type I error was protected only for the above comparisons. The following comparisons were not included in the hierarchical testing sequence and were therefore considered descriptive (nominal p-values). The treatment difference for Tio 5 µg vs. placebo was L for FEV 1 AUC 0-3h response and L for trough FEV 1 response ( p<0.00 for both lung function endpoints). The treatment difference for the adjusted mean SGRQ total score for Tio 5 µg vs. placebo was points based on individual trial data from and points based on combined data (p = and p = , respectively). Treatment differences in favour of the FDCs compared with Tio 5 µg were observed for FEV 1 AUC 0-3h response (0.105 L for T+O 5/5 µg and L for T+O 2.5/5 µg vs. Tio 5 µg, p<0.00 for both comparisons) and for trough FEV 1

8 Page 7 of 10 BI Trial No.: c International GmbH or one or more of its affiliated companies 7 of International GmbH or one or more of its affiliated companies. All rights reserved. response (0.039 L for T+O 5/5 µg and L for T+O 2.5/5 µg vs. Tio 5 µg, p = and p = , respectively). Treatment differences in favour of the FDCs compared with Tio 5 µg were also observed for the SGRQ total score for both, the individual trial data from ( points for T+O 5/5 µg and points for T+O 2.5/5 µg vs. Tio 5 µg, p = and p = , respectively) and the combined data( points for Tio+Olo 5/5 µg and points for Tio+Olo 2.5/5 µg vs. Tio 5 µg, p = and p = , respectively). Secondary efficacy endpoints: The analyses of secondary endpoints are descriptive, and p-values for treatment comparisons are nominal. TDI focal score after 12 weeks of treatment The adjusted mean TDI focal score after 12 weeks of treatment was higher (better) for the Tio+Olo FDCs than for placebo or Tio 5 µg in both, the individual trial data from (placebo: [SE 0.195] points, Tio 5 μg: [0.191] points, T+O 2.5/5 μg: [0.189] points, T+O 5/5 μg: [0.187] points) and the combined trial data (placebo: [0.139] points, Tio 5 μg: [0.136] points, T+O 2.5/5 μg: [0.134] points, T+O 5/5 μg: [0.134] points). The scores obtained from both data sources (individual and combined data) were comparable. Based on individual trial data from , the treatment difference was points for Tio+Olo 5/5 µg vs. placebo and points for Tio+Olo 2.5/5 µg vs. placebo (p<0.00 for both comparisons). The treatment difference for Tio 5 µg vs. placebo was points (p = ). Based on combined data, the treatment difference was points for Tio+Olo 5/5 µg vs. placebo and 1.611points for Tio+Olo 2.5/5 µg vs. placebo; the treatment difference for Tio 5 µg vs. placebo was points (p<0.00 for all comparisons). Treatment differences in favour of the FDCs compared with Tio 5 µg were observed for both, the individual trial data from (0.582 points for T+O 5/5 µg and points for T+O 2.5/5 µg vs. Tio 5 µg, p = and p = 0.59, respectively) and the combined data (0.594 points for T+O 5/5 µg and

9 Page 8 of 10 BI Trial No.: c International GmbH or one or more of its affiliated companies 8 of International GmbH or one or more of its affiliated companies. All rights reserved. Safety Results: points for T+O 2.5/5 µg vs. Tio 5 µg, p = 0.09 and p = , respectively). FVC AUC 0-3h response and trough FVC response (changes from baseline) after 12 weeks of treatment The results for the adjusted mean FVC AUC 0-3h responses after 12 weeks of treatment were in line with the FEV 1 data and were clearly larger for the 2 FDCs than for placebo and Tio 5 µg (placebo: -0.8, [SE 0.025] L, Tio 5 μg: [0.023] L, T+O 2.5/5 μg: [0.024] L, T+O 5/5 μg: [0.023] L). The difference to placebo was L for Tio+Olo 5/5 μg and L for Tio+Olo 2.5/5 µg (p<0.00 for both comparisons). The adjusted mean trough FVC responses showed a similar pattern (placebo: [SE 0.024] L, Tio 5 μg: [0.023] L, T+O 2.5/5 μg: [0.023] L, T+O 5/5 μg: [0.023] L). The difference to placebo was L for Tio+Olo 5/5 μg and L for Tio+Olo 2.5/5 μg (p<0.00 for both comparisons). The treatment differences for Tio 5 µg vs. placebo were L for the FVC AUC 0-3h response and L for the trough FVC response (p<0.00 for both lung function endpoints). Treatment differences in favour of the FDCs compared with Tio 5 µg were observed for FVC AUC 0-3h response (0.148 L for Tio+Olo 5/5 µg and L for Tio+Olo 2.5/5 µg vs. Tio 5 µg, p<0.00 for both comparisons) and for trough FVC response (0.061 L for Tio+Olo 5/5 µg and L for Tio+Olo 2.5/5 µg vs. Tio 5 µg, p = and p = , respectively). Further (non-secondary) endpoints are not presented here. Overall, 45.1% of patients reported at least 1 AE during the trial, and the incidence was similar between the treatment groups (placebo: 46.0%, Tio 5 μg: 45.8%, T+O 2.5/5 μg: 45.5%, T+O 5/5 μg: 43.1%). Consistent with the population under study, the most frequently reported AEs by SOC were respiratory, thoracic and mediastinal disorders (16.2% overall) and infections and infestations (15.7% overall). AEs reported for more than 2.0% of patients overall were COPD (lowest level term COPD exacerbation; 6.2%), nasopharyngitis (4.3%), cough (3.1%), dyspnoea (3.0%), and upper respiratory

10 Page 9 of 10 BI Trial No.: c International GmbH or one or more of its affiliated companies 9 of International GmbH or one or more of its affiliated companies. All rights reserved. tract infection (2.3%). The incidence of cough and dyspnoea was higher in the placebo group than in the active treatment groups; for other common AEs, incidences were generally comparable across the treatment groups, and there was no indication of a tiotropium dose relationship for the combination therapies. The majority of AEs were mild to moderate in intensity; severe AEs were reported for 22 patients (2.7%) overall, with similar frequencies in the T+O 5/5 μg and placebo groups. Drug-related AEs (as assessed by the investigator) were reported for 35 patients (4.3%) overall. The most commonly reported related AEs were cough, reported for 6 patients (0.7%), and dyspnoea and COPD, each reported for 4 patients (0.5%). There were no noteworthy differences between the treatment groups with regard to specific drug-related AEs. One patient died during the trial (T+O 5/5 µg group). The fatal AE (myocardial infarction) was not considered to be drug-related by the investigator. Overall, 26 patients (3.2%) experienced at least 1 serious adverse event (SAE) during the treatment period (placebo: 2.0%, Tio 5 μg: 5.9%, T+O 2.5/5 μg: 2.0%, T+O 5/5 μg: 3.0%). The most frequent SAEs by SOC were cardiac disorders, reported for a total of 7 patients (0.9%): 3 patients each in the Tio 5 µg and Tio+Olo 5/5 µg groups, and 1 patient in the placebo group. SAEs that were reported for more than 2 patients overall were myocardial infarction, COPD, and musculoskeletal chest pain (3 patients each). One case of myocardial infarction in the Tio+Olo 5/5 µg group was fatal. All but one of the patients with cardiac SAEs had pre-existing coronary heart disease and/or cardiovascular risk factors. There were no notable differences between the treatment groups with regard to specific SAEs. SAEs reported for 2 patients (T+O 2.5/5 μg group) were considered to be drug-related by the investigator (cellulitis in 1 patient and rash in 1 patient). A total of 22 patients (2.7%) experienced AEs that led to discontinuation of study medication, with the highest incidence being observed in the placebo group (placebo: 5.0%, Tio 5 μg: 3.4%, T+O 2.5/5 μg: 2.0%, T+O 5/5 μg: 0.5%). AEs leading to treatment discontinuation that were reported for more than 2 patients overall were COPD (7 patients), dyspnoea (5 patients), and cough (3 patients). Vital signs measurements were similar between treatment groups. No dose- or time- related trends or patterns were observed.

11 Page 10 of 10 BI Trial No.: c International GmbH or one or more of its affiliated companies 10 of International GmbH or one or more of its affiliated companies. All rights reserved. Conclusions: With respect to the lung function primary endpoints (FEV 1 AUC 0-3h response, trough FEV 1 response after 12 weeks), trial confirmed the benefit of Tio+Olo 5/5 μg and Tio+Olo 2.5/5 μg compared with placebo. With respect to the symptomatic primary endpoint (SGRQ total score after 12 weeks), trial and the combined dataset from and confirmed the benefit of Tio+Olo 5/5 μg compared with placebo, with an effect size greater than the minimum clinically important difference (MCID) of 4.0 points. A benefit of Tio+Olo 2.5/5 μg compared with placebo for the SGRQ total score was also confirmed, however, with an effect size that was below the MCID for both trial and the combined dataset. Tio+Olo 5/5 μg and Tio+Olo 2.5/5 μg were well tolerated; no safety concerns were identified in the trial.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

Sponsor Novartis Pharmaceuticals

Sponsor Novartis Pharmaceuticals Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Generic Drug Name Indacaterol Therapeutic Area of Trial Chronic Obstructive Pulmonary Disease (COPD) Indication studied: COPD Study

More information

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical

More information

Bronchodilators in COPD

Bronchodilators in COPD TSANZSRS Gold Coast 2015 Can average outcomes in COPD clinical trials guide treatment strategies? Long live the FEV1? Christine McDonald Dept of Respiratory and Sleep Medicine Austin Health Institute for

More information

Sponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.

Sponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational. Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Sponsor Novartis. Generic Drug Name Secukinumab. Therapeutic Area of Trial Psoriasis. Approved Indication investigational

Sponsor Novartis. Generic Drug Name Secukinumab. Therapeutic Area of Trial Psoriasis. Approved Indication investigational Clinical Trial Results Database Page 2 Sponsor Novartis Generic Drug Name Secukinumab Therapeutic Area of Trial Psoriasis Approved Indication investigational Clinical Trial Results Database Page 3 Study

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

2.0 Synopsis. Vicodin CR (ABT-712) M05-765 Clinical Study Report R&D/07/095. (For National Authority Use Only) to Part of Dossier: Volume:

2.0 Synopsis. Vicodin CR (ABT-712) M05-765 Clinical Study Report R&D/07/095. (For National Authority Use Only) to Part of Dossier: Volume: 2.0 Synopsis Abbott Laboratories Name of Study Drug: Vicodin CR Name of Active Ingredient: Hydrocodone/Acetaminophen Extended Release (ABT-712) Individual Study Table Referring to Part of Dossier: Volume:

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Shaikha Al Naimi Doctor of Pharmacy Student College of Pharmacy Qatar University

More information

SYNOPSIS. Risperidone: Clinical Study Report CR003274

SYNOPSIS. Risperidone: Clinical Study Report CR003274 SYNOPSIS Protocol No: CR003274 Title of Study: An Open-Label, Long-Term Trial of Risperidone Long-Acting Microspheres in the Treatment of Subjects Diagnosed with Schizophrenia Coordinating Investigator:

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Exploratory data: COPD and blood eosinophils. David Price: 9.23-9.35am

Exploratory data: COPD and blood eosinophils. David Price: 9.23-9.35am Exploratory data: COPD and blood eosinophils David Price: 9.23-9.35am Blood Eosinophilia in COPD The reliability and utility of blood eosinophils as a marker of disease burden, healthcare resource utilisation

More information

Phase: IV. Study Period: 20 Jan. 2006-17 Sep. 2008

Phase: IV. Study Period: 20 Jan. 2006-17 Sep. 2008 The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

SYNOPSIS. 2-Year (0.5 DB + 1.5 OL) Addendum to Clinical Study Report

SYNOPSIS. 2-Year (0.5 DB + 1.5 OL) Addendum to Clinical Study Report Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abatacept () Name of Active Ingredient: Abatacept () Individual Study Table Referring to the Dossier (For National Authority Use

More information

1.0 Abstract. Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA. Keywords. Rationale and Background:

1.0 Abstract. Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA. Keywords. Rationale and Background: 1.0 Abstract Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA Keywords Rationale and Background: This abbreviated clinical study report is based on a clinical surveillance

More information

PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain

PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain P a g e 1 PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain Clinical Phase 4 Study Centers Study Period 25 U.S. sites identified and reviewed by the Steering Committee and Contract

More information

Re: LUMIGAN 0.03% (bimatoprost ophthalmic solution 0.03%) and LUMIGAN 0.01% (bimatoprost ophthalmic solution 0.01%)

Re: LUMIGAN 0.03% (bimatoprost ophthalmic solution 0.03%) and LUMIGAN 0.01% (bimatoprost ophthalmic solution 0.01%) Allergan Ltd, 1st Floor, Marlow International, Parkway, Marlow, Bucks SL7 1YL Tel: (01628) 494444 Facsimile: (01628) 494449 Ref No: UK15-000677 Mandeep Allingham NW Surrey CCG February 18, 2015 Dear Ms

More information

NCT00272090. sanofi-aventis HOE901_3507. insulin glargine

NCT00272090. sanofi-aventis HOE901_3507. insulin glargine These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Longitudinal Modeling of Lung Function in Respiratory Drug Development

Longitudinal Modeling of Lung Function in Respiratory Drug Development Longitudinal Modeling of Lung Function in Respiratory Drug Development Fredrik Öhrn, PhD Senior Clinical Pharmacometrician Quantitative Clinical Pharmacology AstraZeneca R&D Mölndal, Sweden Outline A brief

More information

Riociguat Clinical Trial Program

Riociguat Clinical Trial Program Riociguat Clinical Trial Program Riociguat (BAY 63-2521) is an oral agent being investigated as a new approach to treat chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension

More information

Prevention of Acute COPD exacerbations

Prevention of Acute COPD exacerbations December 3, 2015 Prevention of Acute COPD exacerbations George Pyrgos MD 1 Disclosures No funding received for this presentation I have previously conducted clinical trials with Boehringer Ingelheim. Principal

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Afrezza Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization

More information

Humulin (LY041001) Page 1 of 1

Humulin (LY041001) Page 1 of 1 (LY041001) These clinical study results are supplied for informational purposes only in the interests of scientific disclosure. They are not intended to substitute for the FDA-approved package insert or

More information

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril,

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Chronic obstructive pulmonary disease. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study

Chronic obstructive pulmonary disease. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study Eur Respir J 212; 4: 83 836 DOI: 1.1183/931936.225511 CopyrightßERS 212 Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study Paul W. Jones*, Dave Singh, Eric D. Bateman

More information

Version History. Previous Versions. Drugs for MS.Drug facts box fingolimod Version 1.0 Author

Version History. Previous Versions. Drugs for MS.Drug facts box fingolimod Version 1.0 Author Version History Policy Title Drugs for MS.Drug facts box fingolimod Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields as required

More information

CLINICAL STUDY REPORT SYNOPSIS

CLINICAL STUDY REPORT SYNOPSIS CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-6511351:2.0 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Protocol No.: CR002353 Johnson & Johnson Pharmaceutical

More information

TUTORIAL on ICH E9 and Other Statistical Regulatory Guidance. Session 1: ICH E9 and E10. PSI Conference, May 2011

TUTORIAL on ICH E9 and Other Statistical Regulatory Guidance. Session 1: ICH E9 and E10. PSI Conference, May 2011 TUTORIAL on ICH E9 and Other Statistical Regulatory Guidance Session 1: PSI Conference, May 2011 Kerry Gordon, Quintiles 1 E9, and how to locate it 2 ICH E9 Statistical Principles for Clinical Trials (Issued

More information

Novel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety

Novel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety Novel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety Anders Svensson MD, PhD Head of Global Clinical Development Metabolism, F Hoffmann LaRoche Ltd. Basel, Switzerland Overview of

More information

FREEDOM C: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C

FREEDOM C: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C FREEDOM C: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C SR in Combination with an ERA and/or a PDE-5 Inhibitor

More information

Psoriasis, Incidence, Quality of Life, Psoriatic Arthritis, Prevalence

Psoriasis, Incidence, Quality of Life, Psoriatic Arthritis, Prevalence 1.0 Abstract Title Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients with Psoriasis Severe or Moderate with Adalimumab Treatment (TOGETHER). Keywords Psoriasis,

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website. It is provided for patients and healthcare professionals to increase the transparency of

More information

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains

More information

COPD PROTOCOL CELLO. Leiden

COPD PROTOCOL CELLO. Leiden COPD PROTOCOL CELLO Leiden May 2011 1 Introduction This protocol includes an explanation of the clinical picture, diagnosis, objectives and medication of COPD. The Cello way of working can be viewed on

More information

Analysis and Interpretation of Clinical Trials. How to conclude?

Analysis and Interpretation of Clinical Trials. How to conclude? www.eurordis.org Analysis and Interpretation of Clinical Trials How to conclude? Statistical Issues Dr Ferran Torres Unitat de Suport en Estadística i Metodología - USEM Statistics and Methodology Support

More information

The Consequences of Missing Data in the ATLAS ACS 2-TIMI 51 Trial

The Consequences of Missing Data in the ATLAS ACS 2-TIMI 51 Trial The Consequences of Missing Data in the ATLAS ACS 2-TIMI 51 Trial In this white paper, we will explore the consequences of missing data in the ATLAS ACS 2-TIMI 51 Trial and consider if an alternative approach

More information

A Phase 2 Study of Interferon Beta-1a (Avonex ) in Ulcerative Colitis

A Phase 2 Study of Interferon Beta-1a (Avonex ) in Ulcerative Colitis A Phase 2 Study of (Avonex ) in Ulcerative Colitis - Study Results - ClinicalTrials.gov A Phase 2 Study of (Avonex ) in Ulcerative Colitis This study has been completed. Sponsor: Biogen Idec Information

More information

J of Evolution of Med and Dent Sci/ eissn- 2278-4802, pissn- 2278-4748/ Vol. 3/ Issue 65/Nov 27, 2014 Page 13575

J of Evolution of Med and Dent Sci/ eissn- 2278-4802, pissn- 2278-4748/ Vol. 3/ Issue 65/Nov 27, 2014 Page 13575 EFFECT OF BREATHING EXERCISES ON BIOPHYSIOLOGICAL PARAMETERS AND QUALITY OF LIFE OF PATIENTS WITH COPD AT A TERTIARY CARE CENTRE Sudin Koshy 1, Rugma Pillai S 2 HOW TO CITE THIS ARTICLE: Sudin Koshy, Rugma

More information

Summary 1. Comparative-effectiveness

Summary 1. Comparative-effectiveness Cost-effectiveness of Delta-9-tetrahydrocannabinol/cannabidiol (Sativex ) as add-on treatment, for symptom improvement in patients with moderate to severe spasticity due to MS who have not responded adequately

More information

Clinical Guideline. Recommendation 3: For stable COPD patients with respiratory symptoms

Clinical Guideline. Recommendation 3: For stable COPD patients with respiratory symptoms Clinical Guideline Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians,

More information

Version History. Previous Versions. Drugs for MS.Drug facts box fampridine Version 1.0 Author

Version History. Previous Versions. Drugs for MS.Drug facts box fampridine Version 1.0 Author Version History Policy Title Drugs for MS.Drug facts box fampridine Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields as required

More information

Clinical Guideline. Recommendation 3: For stable COPD patients with respiratory symptoms

Clinical Guideline. Recommendation 3: For stable COPD patients with respiratory symptoms Clinical Guideline Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians,

More information

Statistics and Pharmacokinetics in Clinical Pharmacology Studies

Statistics and Pharmacokinetics in Clinical Pharmacology Studies Paper ST03 Statistics and Pharmacokinetics in Clinical Pharmacology Studies ABSTRACT Amy Newlands, GlaxoSmithKline, Greenford UK The aim of this presentation is to show how we use statistics and pharmacokinetics

More information

Week 12 study results

Week 12 study results Week 12 study results 15 April 2015 Copyright 2015 Galapagos NV Disclaimer This document may contain certain statements, including forward-looking statements, such as statements concerning the safety and

More information

Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes

Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center

More information

Interpretation of Pulmonary Function Tests

Interpretation of Pulmonary Function Tests Interpretation of Pulmonary Function Tests Dr. Sally Osborne Cellular & Physiological Sciences University of British Columbia Room 3602, D.H Copp building 604 822-3421 sally.osborne@ubc.ca www.sallyosborne.com

More information

Outcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital

Outcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital Mahidol University Journal of Pharmaceutical Sciences 008; 35(14): 81. Original Article Outcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital

More information

Testing Multiple Secondary Endpoints in Confirmatory Comparative Studies -- A Regulatory Perspective

Testing Multiple Secondary Endpoints in Confirmatory Comparative Studies -- A Regulatory Perspective Testing Multiple Secondary Endpoints in Confirmatory Comparative Studies -- A Regulatory Perspective Lilly Yue, Ph.D. Chief, Cardiovascular and Ophthalmic Devices Branch Division of Biostatistics CDRH/FDA

More information

Novartis Gilenya FDO Program Clinical Protocol and Highlights from Prescribing Information (PI)

Novartis Gilenya FDO Program Clinical Protocol and Highlights from Prescribing Information (PI) Novartis Gilenya FDO Program Clinical Protocol and Highlights from Prescribing Information (PI) Highlights from Prescribing Information - the link to the full text PI is as follows: http://www.pharma.us.novartis.com/product/pi/pdf/gilenya.pdf

More information

Adoption by CHMP for release for consultation November 2010. End of consultation (deadline for comments) 31 March 2011

Adoption by CHMP for release for consultation November 2010. End of consultation (deadline for comments) 31 March 2011 1 2 3 November 2010 EMA/759784/2010 Committee for Medicinal Products for Human Use 4 5 6 7 Reflection paper on the need for active control in therapeutic areas where use of placebo is deemed ethical and

More information

2. Background This drug had not previously been considered by the PBAC.

2. Background This drug had not previously been considered by the PBAC. PUBLIC SUMMARY DOCUMENT Product: Ambrisentan, tablets, 5 mg and 10 mg, Volibris Sponsor: GlaxoSmithKline Australia Pty Ltd Date of PBAC Consideration: July 2009 1. Purpose of Application The submission

More information

Biostat Methods STAT 5820/6910 Handout #6: Intro. to Clinical Trials (Matthews text)

Biostat Methods STAT 5820/6910 Handout #6: Intro. to Clinical Trials (Matthews text) Biostat Methods STAT 5820/6910 Handout #6: Intro. to Clinical Trials (Matthews text) Key features of RCT (randomized controlled trial) One group (treatment) receives its treatment at the same time another

More information

Guideline on missing data in confirmatory clinical trials

Guideline on missing data in confirmatory clinical trials 2 July 2010 EMA/CPMP/EWP/1776/99 Rev. 1 Committee for Medicinal Products for Human Use (CHMP) Guideline on missing data in confirmatory clinical trials Discussion in the Efficacy Working Party June 1999/

More information

ID: C13006 Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis NCT00783718 Results Preview Close

ID: C13006 Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis NCT00783718 Results Preview Close Home > Record Summary > Results Section ID: C13006 Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis NCT00783718 Results Preview Close Hide All Participant Flow Participants

More information

TEMPLATE DATA MANAGEMENT PLAN

TEMPLATE DATA MANAGEMENT PLAN TEMPLATE DATA MANAGEMENT PLAN ICRIN (QM sub group) Version: XX Date: XXXXXXX Page 1 of 6 1.0 Document Ownership The Data Management Plan (DMP) will be initiated and subsequently owned by the Data Manager

More information

Prof. Florian Gantner. Vice President Respiratory Diseases Research Boehringer Ingelheim

Prof. Florian Gantner. Vice President Respiratory Diseases Research Boehringer Ingelheim Prof. Florian Gantner Vice President Respiratory Diseases Research Boehringer Ingelheim Research and Development in Practice: COPD Chronic Obstructive Pulmonary Disease (COPD) Facts Main cause of COPD

More information

MISSING DATA: THE POINT OF VIEW OF ETHICAL COMMITTEES

MISSING DATA: THE POINT OF VIEW OF ETHICAL COMMITTEES I CONGRESSO NAZIONALE BIAS 2009 29/30 APRILE 2009 ELI LILLY SESTO FIORENTINO (FI) MISSING DATA: THE POINT OF VIEW OF ETHICAL COMMITTEES Anna Chiara Frigo Department of Environmental Medicine and Public

More information

Treatment for. Malaria: DHA/PQP. Science Day MMV Stakeholders Meeting. Defeating Malaria Together 1

Treatment for. Malaria: DHA/PQP. Science Day MMV Stakeholders Meeting. Defeating Malaria Together 1 ANewOnce-a-day Treatment for Uncomplicated Malaria: DHA/PQP Science Day MMV Stakeholders Meeting Dr. Ambrose Talisuna Former Director Global Access, MMV & Field Coordinator, African Eurartesim Registration

More information

If several different trials are mentioned in one publication, the data of each should be extracted in a separate data extraction form.

If several different trials are mentioned in one publication, the data of each should be extracted in a separate data extraction form. General Remarks This template of a data extraction form is intended to help you to start developing your own data extraction form, it certainly has to be adapted to your specific question. Delete unnecessary

More information

Kanıt: Klinik çalışmalarda ZYTIGA

Kanıt: Klinik çalışmalarda ZYTIGA mkdpk de Sonunda Gerçek İlerleme! Kanıt: Klinik çalışmalarda ZYTIGA Dr. Sevil Bavbek 5. Türk Tıbbi Onkoloji Kongresi Mart 214, Antalya Endocrine therapies Adrenals Testis Abiraterone Orteronel Androgen

More information

PG Certificate / PG Diploma / MSc in Clinical Pharmacy

PG Certificate / PG Diploma / MSc in Clinical Pharmacy PG Certificate / PG Diploma / MSc in Clinical Pharmacy Programme Information September 2014 Entry School of Pharmacy Queen s University Belfast Queen s University Belfast - Clinical Pharmacy programme

More information

The importance of adherence and persistence: The advantages of once-daily dosing

The importance of adherence and persistence: The advantages of once-daily dosing The importance of adherence and persistence: The advantages of once-daily dosing Craig I. Coleman, PharmD Professor, University of Connecticut School of Pharmacy Storrs, CT, USA Conflicts of interest Dr

More information

"Statistical methods are objective methods by which group trends are abstracted from observations on many separate individuals." 1

Statistical methods are objective methods by which group trends are abstracted from observations on many separate individuals. 1 BASIC STATISTICAL THEORY / 3 CHAPTER ONE BASIC STATISTICAL THEORY "Statistical methods are objective methods by which group trends are abstracted from observations on many separate individuals." 1 Medicine

More information

New Evidence reports on presentations given at EULAR 2012. Rituximab for the Treatment of Rheumatoid Arthritis

New Evidence reports on presentations given at EULAR 2012. Rituximab for the Treatment of Rheumatoid Arthritis New Evidence reports on presentations given at EULAR 2012 Rituximab for the Treatment of Rheumatoid Arthritis Report on EULAR 2012 presentations Long-term safety of rituximab: 10-year follow-up in the

More information

II. DISTRIBUTIONS distribution normal distribution. standard scores

II. DISTRIBUTIONS distribution normal distribution. standard scores Appendix D Basic Measurement And Statistics The following information was developed by Steven Rothke, PhD, Department of Psychology, Rehabilitation Institute of Chicago (RIC) and expanded by Mary F. Schmidt,

More information

The submission positioned dimethyl fumarate as a first-line treatment option.

The submission positioned dimethyl fumarate as a first-line treatment option. Product: Dimethyl Fumarate, capsules, 120 mg and 240 mg, Tecfidera Sponsor: Biogen Idec Australia Pty Ltd Date of PBAC Consideration: July 2013 1. Purpose of Application The major submission sought an

More information

Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure

Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure 703 1 of 11 POLICY The Beaumont Research Coordinating Center (BRCC) will provide advice to clinical trial investigators on protocol development, content and format. Upon request, the BRCC will review a

More information

Rapid Critical Appraisal of Controlled Trials

Rapid Critical Appraisal of Controlled Trials Rapid Critical Appraisal of Controlled Trials Carl Heneghan Dept of Primary Health Care University of Oxford November 23rd 2009 Five steps in EBM 1. Formulate an answerable question 2. Track down the best

More information

Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results

Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Paul K. Whelton, MB, MD, MSc Chair, SPRINT Steering Committee Tulane University School of Public Health and Tropical Medicine, and

More information

Harmony Clinical Trial Medical Media Factsheet

Harmony Clinical Trial Medical Media Factsheet Overview Harmony is the global Phase III clinical trial program for Tanzeum (albiglutide), a product developed by GSK for the treatment of type 2 diabetes. The comprehensive program comprised eight individual

More information

QT analysis: A guide for statistical programmers. Prabhakar Munkampalli Statistical Analyst II Hyderabad, 7 th September 2012

QT analysis: A guide for statistical programmers. Prabhakar Munkampalli Statistical Analyst II Hyderabad, 7 th September 2012 QT analysis: A guide for statistical programmers Prabhakar Munkampalli Statistical Analyst II Hyderabad, 7 th September 2012 Agenda ECG ICH E14 Thorough QT/QTc study Role of Statistical Programmer References

More information

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Guidance for Industry Acute Bacterial Exacerbations of Chronic Bronchitis in Patients With Chronic Obstructive Pulmonary Disease: Developing Antimicrobial Drugs for Treatment U.S. Department of Health

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

COPD MANAGEMENT PROTOCOL STANFORD COORDINATED CARE

COPD MANAGEMENT PROTOCOL STANFORD COORDINATED CARE I. PURPOSE To establish guidelines f the collabative management of patients with a diagnosis of chronic obstructive pulmonary disease (COPD) who are not adequately controlled and to define the roles and

More information

to Part of Dossier: Name of Active Ingredient: Title of Study: Quality of life study with adalimumab in rheumatoid arthritis. ESCALAR.

to Part of Dossier: Name of Active Ingredient: Title of Study: Quality of life study with adalimumab in rheumatoid arthritis. ESCALAR. 2.0 Synopsis Abbott Laboratories Name of Study Drug: Individual Study Table Referring to Part of Dossier: Adalimumab (HUMIRA) (For National Authority Use Only) Name of Active Ingredient: Adalimumab Title

More information

Before prescribing for COPD management, the patient should have had appropriate assessment, including spirometry, as per NICE guidelines.

Before prescribing for COPD management, the patient should have had appropriate assessment, including spirometry, as per NICE guidelines. Formulary Guidance for Management of COPD patients Before prescribing for COPD management, the patient should have had appropriate assessment, including spirometry, as per NICE guidelines. For inhaler

More information

Clinical Research Pediatric Pulmonary Division

Clinical Research Pediatric Pulmonary Division Clinical Research Pediatric Pulmonary Division Hengameh H. Raissy, PharmD Research Associate Professor, Pediatric Pulmonary UNM HSC Director of Clinical Trials Presented at Envision NM Asthma / Pulmonary

More information

33 % of whiplash patients develop. headaches originating from the upper. cervical spine

33 % of whiplash patients develop. headaches originating from the upper. cervical spine 33 % of whiplash patients develop headaches originating from the upper cervical spine - Dr Nikolai Bogduk Spine, 1995 1 Physical Treatments for Headache: A Structured Review Headache: The Journal of Head

More information

COPD and Asthma Differential Diagnosis

COPD and Asthma Differential Diagnosis COPD and Asthma Differential Diagnosis Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death in America. Learning Objectives Use tools to effectively diagnose chronic obstructive

More information

STATISTICAL ANALYSIS OF SAFETY DATA IN LONG-TERM CLINICAL TRIALS

STATISTICAL ANALYSIS OF SAFETY DATA IN LONG-TERM CLINICAL TRIALS STATISTICAL ANALYSIS OF SAFETY DATA IN LONG-TERM CLINICAL TRIALS Tailiang Xie, Ping Zhao and Joel Waksman, Wyeth Consumer Healthcare Five Giralda Farms, Madison, NJ 794 KEY WORDS: Safety Data, Adverse

More information

Basic research methods. Basic research methods. Question: BRM.2. Question: BRM.1

Basic research methods. Basic research methods. Question: BRM.2. Question: BRM.1 BRM.1 The proportion of individuals with a particular disease who die from that condition is called... BRM.2 This study design examines factors that may contribute to a condition by comparing subjects

More information

Cost-effectiveness of Pirfenidone (Esbriet ) for the treatment of Idiopathic Pulmonary Fibrosis.

Cost-effectiveness of Pirfenidone (Esbriet ) for the treatment of Idiopathic Pulmonary Fibrosis. Cost-effectiveness of Pirfenidone (Esbriet ) for the treatment of Idiopathic Pulmonary Fibrosis. March 2013 1. Pirfenidone is indicated in adults for the treatment of mild to moderate Idiopathic Pulmonary

More information

Sponsor / Company: Sanofi Drug substance(s): HOE901 (insulin glargine)

Sponsor / Company: Sanofi Drug substance(s): HOE901 (insulin glargine) These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

Nursing Journal Toolkit: Critiquing a Quantitative Research Article

Nursing Journal Toolkit: Critiquing a Quantitative Research Article A Virtual World Consortium: Using Second Life to Facilitate Nursing Journal Clubs Nursing Journal Toolkit: Critiquing a Quantitative Research Article 1. Guidelines for Critiquing a Quantitative Research

More information

This can dilute the significance of a departure from the null hypothesis. We can focus the test on departures of a particular form.

This can dilute the significance of a departure from the null hypothesis. We can focus the test on departures of a particular form. One-Degree-of-Freedom Tests Test for group occasion interactions has (number of groups 1) number of occasions 1) degrees of freedom. This can dilute the significance of a departure from the null hypothesis.

More information

WAY OF WORKING LUNG PATIENTS

WAY OF WORKING LUNG PATIENTS WAY OF WORKING LUNG PATIENTS CELLO Leiden May 2011 Introduction CELLO, the cooperation of primary health care practitioners in Leiden and surroundings, is an organisation of independently working general

More information

PCOM Letterhead [Substitute same from participating institution and, of course, change Department, PI, and Co-Investigators]

PCOM Letterhead [Substitute same from participating institution and, of course, change Department, PI, and Co-Investigators] PCOM Letterhead [Substitute same from participating institution and, of course, change Department, PI, and Co-Investigators] Department of Neuroscience, Physiology and Pharmacology 215-871-6880 PATIENT

More information

Pulmonary Rehabilitation in Newark and Sherwood

Pulmonary Rehabilitation in Newark and Sherwood Pulmonary Rehabilitation in Newark and Sherwood With exception of smoking cessation pulmonary rehabilitation is the single most effective intervention for any patient with COPD. A Cochrane review published

More information

THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT

THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological

More information

DUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania

DUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY (DAPT) Dual antiplatelet regimen

More information

Efficacy, safety and preference study of a insulin pen PDS290 vs. a Novo Nordisk marketed insulin pen in diabetics

Efficacy, safety and preference study of a insulin pen PDS290 vs. a Novo Nordisk marketed insulin pen in diabetics Efficacy, safety and preference study of a insulin pen PDS290 vs. a Novo Nordisk marketed insulin pen in diabetics This trial is conducted in the United States of America (USA). The aim of this clinical

More information

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7

More information

Breathing Easier In Tennessee: Employers Mitigate Health and Economic Costs of Chronic Obstructive Pulmonary Disease

Breathing Easier In Tennessee: Employers Mitigate Health and Economic Costs of Chronic Obstructive Pulmonary Disease Breathing Easier In Tennessee: Employers Mitigate Health and Economic Costs of Chronic Obstructive Pulmonary Disease By John W. Walsh, Co-Founder and President of the COPD Foundation Breathing Easier In

More information

Addendum to Clinical Review for NDA 22-512

Addendum to Clinical Review for NDA 22-512 Addendum to Clinical Review for DA 22-512 Drug: Sponsor: Indication: Division: Reviewers: dabigatran (Pradaxa) Boehringer Ingelheim Prevention of stroke and systemic embolism in atrial fibrillation Division

More information

SUPPLEMENTARY MATERIALS. Rivaroxaban for Stroke Prevention in East Asian Patients from the ROCKET AF Trial

SUPPLEMENTARY MATERIALS. Rivaroxaban for Stroke Prevention in East Asian Patients from the ROCKET AF Trial 1 SUPPLEMENTARY MATERIALS Rivaroxaban for Stroke Prevention in East Asian Patients from the ROCKET AF Trial Professor Ka Sing Lawrence Wong on behalf of The Executive Steering Committee and the ROCKET

More information

Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author

Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author Version History Policy Title Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further

More information